Skip to content

TRIFORCE Life Science

Active Private limited companyfounded 2023active for 3 yearsHoge Bokstraat 134, 9111 Sint-NiklaasKBO/BCE: BE 0801.301.657

Lifetime

2 annual accounts with figures on one time axis
peak of €24,541 in 2024
€9,548▼ 61.1%
peak of €13,308 in 2024
€4,784▼ 64.1%
peak of €19,433 in 2025
€19,433▲ 25.3%
€6,818▲ 18.4%
Board1 name since 2023
1 director
Documentsfilings and deeds
30-06-202631 days before the deadline
2025micro format
Gross margin from €24,541 to €9,548Result from €13,308 to €4,784Dividend €859Equity from €15,508 to €19,433Debts from €5,759 to €6,818Cash from €8,811 to €13,905

Key points

from the 2025 annual accounts

Equity

€19,433 ▲ 25.3%
15,5082024+4,784Profit-859Dividend19,4332025

TRIFORCE Life Science paid out €859 in dividends. That is 18% of the 2025 profit.

Turnover

≈ €71,000 estimated

The micro format states no turnover.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 39,332 companies had the same profile as TRIFORCE Life Science has now. Each dot stands for 99 companies, two years later.

95.7%
were still trading
2.4%
stopped another way
1.8%
went bankrupt
  • Micro
  • 2 to 5 years old
  • solvency 30% or more
  • a profit of 5% of the balance sheet or more
Test of the method

The method was tested on the 497,994 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 39,332 companies, not a prediction for TRIFORCE Life Science. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Director
  • 100 sharesdeed of 03-05-2023
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0801301657
Incorporation Founding capital of €3,000, 100 shares · Founded by · (director) and (successor director) appointed · published on 03-05-2023 · Gazette deed
First establishment Hoge Bokstraat 134, Sint-Niklaas
All 5 events

Comparable companies

same main activity, similar in size and age
Company
TRIFORCE Life Science Sint-Niklaas €26,251 €9,548 74.0% -
CX-BELUX Zottegem €28,930 €8,558 46.6% -
Roland Holst Consultancy Antwerp €27,188 €9,020 65.9% -
Kullsom Nieuwpoort €20,608 €11,974 37.0% -
AC Real Estate Brussels €33,676 €7,179 69.4% -
Monsieurs BS Wuustwezel €34,614 €12,596 52.2% -
Interpro Blancquaert Waasmunster €41,814 €8,795 47.3% -

These companies have the same main activity as TRIFORCE Life Science: other information service activities (NACE 63920). They are comparable in size and age: total assets between €20,600 and €41,800, founded between 2022 and 2023.

Official details

Source: KBO
Status
Active since 28-04-2023Normal situation
Activity
Other information service activitiesNACE 63920and 5 others
Establishment unit
2.345.565.7109111 Sint-Niklaas, since 28-04-2023
Financial year end
31 December
Peppol
Reachable since 06-01-2025
Company details

Annual accounts 2025

€26,251▲ 23.4%
Filing
Filed on 30-06-2026, 31 days before the end of the filing period
Financials

Insights on TRIFORCE Life Science

TRIFORCE Life Science has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €19,433 and a net result of €4,784.

Its solvency ranks better than 70% of 2,413 sector peers (NACE 63) in financial year 2025.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about TRIFORCE Life Science

What is the company number of TRIFORCE Life Science?
The company number of TRIFORCE Life Science is 0801.301.657. The VAT number is the same number with BE in front: BE 0801.301.657.
Where is TRIFORCE Life Science based?
The registered office is at Hoge Bokstraat 134, 9111 Sint-Niklaas.Company details
What does TRIFORCE Life Science do?
According to the KBO register, the main activity is other information service activities (NACE 63920).
What is the legal form of TRIFORCE Life Science?
TRIFORCE Life Science is a private limited company (BV).
When was TRIFORCE Life Science founded?
TRIFORCE Life Science was founded on 28-04-2023.
Is TRIFORCE Life Science still active?
Yes, TRIFORCE Life Science is an active enterprise in the KBO register.
What is the turnover of TRIFORCE Life Science?
The turnover in financial year 2025 is about €71,000. This figure is estimated from the gross margin of €9,548 and 7,102 comparable companies of the same size. It probably lies between €32,000 and €170,000. It is a rough estimate.Financials
Is TRIFORCE Life Science profitable?
In financial year 2025, TRIFORCE Life Science made a profit of €4,784.
Where can I find the annual accounts of TRIFORCE Life Science?
TRIFORCE Life Science filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of TRIFORCE Life Science due?
TRIFORCE Life Science must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.